文献速递区域麻醉与超声术前评估与围术期医学

肝切除患者硬膜外输注布比卡因的血浆总浓度与游离浓度研究

Plasma bupivacaine levels (total and free/unbound) during epidural infusion in liver resection patients: a prospective, observational study.
PubMed 文献 · Reg Anesth Pain Med · 2022-08-24

这项前瞻性观察研究纳入19例肝切除患者,术后持续硬膜外输注布比卡因,检测血浆总布比卡因、游离布比卡因及α1-酸性糖蛋白(AAG)水平。结果发现游离布比卡因浓度整体升高,部分患者接近毒性阈值,47%报告至少一种局部麻醉药全身毒性(LAST)症状,但无因LAST终止硬膜外镇痛。

要点

  • 肝切除患者术后持续硬膜外布比卡因输注时游离浓度升高,需警惕LAST。
  • 47%患者报告至少一种LAST症状,但无因此终止硬膜外镇痛。
  • AAG反应减弱,直至术后第2天仍降低,幅度与切除重量成比例。

核心结论

  • 肝切除患者术后持续硬膜外输注布比卡因时游离浓度升高,可能增加LAST易感性。

研究设计与样本

  • 前瞻性观察研究,19例肝切除患者完成,术前、麻醉后监护室、术后第2天及第3/4天停硬膜外前采血。

主要发现

  • 血浆总布比卡因与总给药量相关,但游离布比卡因与总给药量无关。
  • 与非肝切除手术不同,术后持续硬膜外给药期间游离布比卡因浓度整体升高。
  • 部分患者接近毒性阈值,47%报告至少一种LAST症状,但无硬膜外因LAST终止。
  • AAG水平直至术后第2天降低,降低幅度与切除重量成比例。

临床怎么用

  • 肝切除患者使用术后持续硬膜外布比卡因输注时,应考虑肝病程度、切除范围和术中失血量。
  • 应警惕LAST的细微和非特异症状,加强监测。

局限性

  • 需未来研究验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Liver resection patients may be at an increased risk of local anesthetic (LA) toxicity because the liver is essential for metabolizing LA and producing proteins (mainly α1-acid glycoprotein (AAG)) that bind to it and reduce the free (and pharmacologically active/toxic) levels in circulation. The liver resection itself, manipulation during surgery, and pre-existing liver disease may all interfere with normal hepatic protein synthesis and result in an attenuation of the increased AAG (a positive acute-phase protein) that normally occurs postoperatively. The purpose of this study was to determine whether the AAG response is attenuated postoperatively following liver resection and whether patients approach toxicity thresholds with continuous postoperative epidural infusion of bupivacaine. METHODS: Prospective, observational study with blood drawn preoperatively, in the postanesthetic care unit, on postoperative day (POD) 2, and prior to discontinuation of epidural analgesia on POD3/POD4. Plasma was analyzed for total and unbound bupivacaine via liquid chromatography-mass spectrometry and AAG via ELISA. Signs/symptoms of local anesthetic systemic toxicity (LAST), pain, and sedation scores were also recorded. RESULTS: For the 19 patients completed, total plasma bupivacaine was correlated with total administered, but unbound levels were not associated with the total administered. Unlike non-hepatectomy surgery where unbound LA plasma levels remain stable (or decrease) with continuous postoperative epidural administration, we observed an overall increase. Several patients approached toxicity thresholds and 47% reported at least one symptom of LAST, but no epidurals were discontinued because of LAST. In contrast to the AAG response reported following major non-liver surgery where AAG levels increase twofold, we observed a reduction until POD2 and the magnitude was proportional to resection weight. DISCUSSION: Our results are supported by the literature in suggesting that major liver resection patients may be at an increased vulnerability for LAST. Factors such as the extent of liver disease, resection and intraoperative blood loss should be considered when using continuous postoperative epidural infusion of bupivacaine and vigilance should be used in monitoring, for signs/symptoms of LAST, even for those subtle and non-specific. Future research will be required to verify these findings. TRIAL REGISTRATION NUMBER: NCT03145805.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Burjorjee J, Phelan R, Hopman WM, et al. Plasma bupivacaine levels (total and free/unbound) during epidural infusion in liver resection patients: a prospective, observational study. Reg Anesth Pain Med. 2022. PMID: 36002226. doi:10.1136/rapm-2022-103683

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。